S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Unique BioPharma Opportunity for Accredited Investors (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NYSE:BHVN

Biohaven (BHVN) Stock Price, News & Analysis

$47.31
-0.02 (-0.04%)
(As of 02/23/2024 ET)
Today's Range
$47.25
$49.61
50-Day Range
$37.92
$49.50
52-Week Range
$12.35
$50.68
Volume
686,976 shs
Average Volume
726,853 shs
Market Capitalization
$3.79 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$47.50

Biohaven MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
0.4% Upside
$47.50 Price Target
Short Interest
Bearish
11.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.67mentions of Biohaven in the last 14 days
Based on 12 Articles This Week
Insider Trading
Selling Shares
$459,690 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From ($5.22) to ($5.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.12 out of 5 stars

Medical Sector

778th out of 943 stocks

Pharmaceutical Preparations Industry

356th out of 431 stocks


BHVN stock logo

About Biohaven Stock (NYSE:BHVN)

Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States. The company's pipeline products include BHV-7000, a potassium channel activator for the treatment of focal epilepsy; BHV-7010, a Kv7 channel modulator for the treatment of different neurological diseases; Troriluzole, a tripeptide prodrug that is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500, a low-trapping glutamate N-methyl-D-aspartate receptor antagonist for neuropathic pain; and Verdiperstat, an oral myeloperoxidase inhibitor, which is in Phase 3 clinical trial for the treatment of neurodegenerative diseases. It also offers Taldefgrobep Alfa, an anti-myostatin adnectin, which is in Phase 3 clinical trial for the treatment of spinal muscle atrophy; and BHV-1100 that is in Phase 1a/1b clinical trial for multiple myeloma patients. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut. Biohaven Ltd. is a subsidiary of Biohaven Pharmaceutical Holding Company Ltd.

BHVN Stock Price History

BHVN Stock News Headlines

BHVN Mar 2024 30.000 put
Gold is SOARING – here's what you need to do
Everything is lining up perfectly for a historic gold bull run. One gold expert says he's found the best way to get in, for just $5.
BHVN Mar 2024 50.000 call
BHVN Oct 2024 70.000 call
A Look At The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Biohaven Pharmaceutical Holding Co Ltd (BHVN)
Stocks to Watch: 3 Companies Working on Next-Gen Weight Loss Drugs
BHVN Jan 2024 50.000 put
BHVN Jul 2024 50.000 call
BHVN Apr 2024 50.000 call
Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
See More Headlines
Receive BHVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biohaven and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
7/31/2023
Today
2/24/2024
Next Earnings (Estimated)
3/28/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Previous Symbol
NASDAQ:BHVN
Fax
N/A
Employees
202
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$47.50
High Stock Price Target
$62.00
Low Stock Price Target
$28.00
Potential Upside/Downside
+0.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
7 Analysts

Profitability

Net Income
$-570,280,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$462.51 million
Book Value
$7.90 per share

Miscellaneous

Free Float
70,255,000
Market Cap
$3.79 billion
Optionable
Optionable
Beta
1.20
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report














BHVN Stock Analysis - Frequently Asked Questions

Should I buy or sell Biohaven stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biohaven in the last year. There are currently 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" BHVN shares.
View BHVN analyst ratings
or view top-rated stocks.

What is Biohaven's stock price target for 2024?

7 brokers have issued twelve-month price objectives for Biohaven's stock. Their BHVN share price targets range from $28.00 to $62.00. On average, they anticipate the company's share price to reach $47.50 in the next twelve months. This suggests a possible upside of 0.4% from the stock's current price.
View analysts price targets for BHVN
or view top-rated stocks among Wall Street analysts.

How have BHVN shares performed in 2024?

Biohaven's stock was trading at $42.80 at the beginning of 2024. Since then, BHVN shares have increased by 10.5% and is now trading at $47.31.
View the best growth stocks for 2024 here
.

Are investors shorting Biohaven?

Biohaven saw a decline in short interest in January. As of January 15th, there was short interest totaling 6,530,000 shares, a decline of 12.7% from the December 31st total of 7,480,000 shares. Based on an average daily trading volume, of 1,170,000 shares, the days-to-cover ratio is presently 5.6 days. Currently, 11.1% of the shares of the stock are short sold.
View Biohaven's Short Interest
.

When is Biohaven's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 28th 2024.
View our BHVN earnings forecast
.

How were Biohaven's earnings last quarter?

Biohaven Ltd. (NYSE:BHVN) released its quarterly earnings data on Monday, July, 31st. The company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.18) by $0.14.

What ETFs hold Biohaven's stock?

ETFs with the largest weight of Biohaven (NYSE:BHVN) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN).Invesco Dorsey Wright Healthcare Momentum ETF (PTH).

What other stocks do shareholders of Biohaven own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biohaven investors own include AbbVie (ABBV), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Alibaba Group (BABA), ACADIA Pharmaceuticals (ACAD), QUALCOMM (QCOM), Pfizer (PFE), Sarepta Therapeutics (SRPT) and Abbott Laboratories (ABT).

When did Biohaven IPO?

(BHVN) raised $124 million in an IPO on Thursday, May 4th 2017. The company issued 8,300,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley, Piper Jaffray and Barclays Capital acted as the underwriters for the IPO and William Blair and Needham & Company were co-managers.

Who are Biohaven's major shareholders?

Biohaven's stock is owned by many different institutional and retail investors. Top institutional investors include Stifel Financial Corp (7.76%), Price T Rowe Associates Inc. MD (3.91%), Price T Rowe Associates Inc. MD (3.91%), Point72 Asset Management L.P. (3.10%), Vanguard Group Inc. (2.07%) and Armistice Capital LLC (1.87%). Insiders that own company stock include Declan Doogan, Elyse Stock, George C Clark, Gregory Bailey, Irina Antonijevic, James Engelhart, John W Childs, Julia P Gregory, Matthew Buten and Vlad Coric.
View institutional ownership trends
.

How do I buy shares of Biohaven?

Shares of BHVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:BHVN) was last updated on 2/24/2024 by MarketBeat.com Staff